David S. Viswanatha

6.8k total citations · 1 hit paper
133 papers, 3.6k citations indexed

About

David S. Viswanatha is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, David S. Viswanatha has authored 133 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Hematology, 67 papers in Genetics and 54 papers in Pathology and Forensic Medicine. Recurrent topics in David S. Viswanatha's work include Acute Myeloid Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (51 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers). David S. Viswanatha is often cited by papers focused on Acute Myeloid Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (51 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers). David S. Viswanatha collaborates with scholars based in United States, Canada and France. David S. Viswanatha's co-authors include Randy D. Gascoyne, Cheryl L. Willman, Joseph M. Connors, Brian Skinnider, Daniel Wu, Andrew J. Coldman, Dennis D. Weisenburger, Stephan W. Morris, Timothy C. Greiner and Julie M. Vose and has published in prestigious journals such as Nature Genetics, Blood and PEDIATRICS.

In The Last Decade

David S. Viswanatha

123 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

2008 542 citations David S. Viswanatha et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David S. Viswanatha United States	32	1.8k	1.2k	1.1k	966	813	133	3.6k
Aspasia Stamatoullas France	34	1.7k 1.0×	1.4k 1.2×	1.3k 1.2×	1.2k 1.2×	701 0.9×	126	3.6k
Sa A. Wang United States	38	1.2k 0.7×	3.2k 2.7×	1.2k 1.1×	1.8k 1.9×	1.1k 1.4×	280	5.4k
Yang O. Huh United States	35	1.3k 0.7×	2.4k 2.1×	1.2k 1.0×	1.6k 1.6×	1.2k 1.5×	104	4.7k
Alessandro Levis Italy	32	2.1k 1.2×	1.1k 1.0×	1.3k 1.1×	616 0.6×	493 0.6×	100	3.8k
Bertram Glaß Germany	26	2.4k 1.4×	922 0.8×	2.2k 2.0×	1000 1.0×	366 0.5×	102	4.1k
Cesare Guglielmi Italy	24	2.3k 1.3×	1.4k 1.2×	1.8k 1.6×	1.3k 1.3×	602 0.7×	67	3.9k
Françoise Rigal‐Huguet France	25	1.0k 0.6×	1.3k 1.1×	869 0.8×	837 0.9×	430 0.5×	66	2.7k
Michèle L. Donato United States	34	784 0.4×	3.2k 2.8×	1.3k 1.1×	766 0.8×	658 0.8×	121	4.4k
Susan Mathew United States	24	787 0.4×	1.0k 0.9×	785 0.7×	548 0.6×	999 1.2×	100	3.3k
Nicolas Ketterer Switzerland	23	2.8k 1.6×	1.1k 0.9×	2.5k 2.2×	1.4k 1.5×	306 0.4×	69	4.5k

Countries citing papers authored by David S. Viswanatha

Since Specialization

Citations

This map shows the geographic impact of David S. Viswanatha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Viswanatha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Viswanatha more than expected).

Fields of papers citing papers by David S. Viswanatha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Viswanatha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Viswanatha. The network helps show where David S. Viswanatha may publish in the future.

Co-authorship network of co-authors of David S. Viswanatha

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Viswanatha. A scholar is included among the top collaborators of David S. Viswanatha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Viswanatha. David S. Viswanatha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kusne, Yael, Talha Badar, Terra L. Lasho, et al.. (2025). Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. British Journal of Haematology. 206(4). 1109–1120. 2 indexed citations

Viswanatha, David S., Dragan Jevremović, James M. Foran, et al.. (2025). Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots. Hematology Reports. 17(3). 26–26.

He, Rong, Patricia T. Greipp, David S. Viswanatha, et al.. (2024). Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience. Blood Advances. 8(18). 4807–4811. 2 indexed citations

Kusne, Yael, Talha Badar, Terra L. Lasho, et al.. (2024). Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome. Blood. 144(Supplement 1). 440–440.

Badar, Talha, Terra L. Lasho, Yael Kusne, et al.. (2024). PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations. Blood. 144(Supplement 1). 3218–3218. 1 indexed citations

He, Rong, David S. Viswanatha, Dragan Jevremović, et al.. (2024). Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms. Leukemia. 38(12). 2727–2730. 1 indexed citations

Badar, Talha, James M. Foran, David S. Viswanatha, et al.. (2023). Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms. Haematologica. 108(11). 3033–3043. 10 indexed citations

Ravindran, Aishwarya, Surendra Dasari, Gordon Ruan, et al.. (2023). Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells. Modern Pathology. 36(10). 100268–100268. 15 indexed citations

Baranwal, Anmol, Rong He, David S. Viswanatha, et al.. (2023). Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Advances. 8(3). 562–570. 1 indexed citations

10.

Gurney, Mark E., Anmol Baranwal, Patricia T. Greipp, et al.. (2023). The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British Journal of Haematology. 202(2). 279–283. 4 indexed citations

11.

Fritcher, Emily G. Barr, et al.. (2023). MICon Contamination Detection Workflow for Next-Generation Sequencing Laboratories Using Microhaplotype Loci and Supervised Learning. Journal of Molecular Diagnostics. 25(8). 602–610. 2 indexed citations

12.

Baranwal, Anmol, Aref Al‐Kali, James M. Foran, et al.. (2022). Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies. Transplantation and Cellular Therapy. 28(3). S126–S127. 1 indexed citations

13.

He, Rong, David S. Viswanatha, Phuong L. Nguyen, et al.. (2022). Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Advances. 7(8). 1351–1355. 9 indexed citations

14.

Tefferi, Ayalew, Naseema Gangat, Aref Al‐Kali, et al.. (2022). A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology. 97(9). 1127–1134. 6 indexed citations

15.

Jenkinson, Garrett, Ross A. Aleff, Christopher A. Hilker, et al.. (2021). Improved Characterization of Complex β-Globin Gene Cluster Structural Variants Using Long-Read Sequencing. Journal of Molecular Diagnostics. 23(12). 1732–1740. 10 indexed citations

16.

Begna, Kebede H., Naseema Gangat, Michelle A. Elliott, et al.. (2021). Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal. 11(3). 46–46. 8 indexed citations

17.

Oliveira, Jennifer L., Lori Frederick, Mrinal M. Patnaik, et al.. (2018). Genotype–phenotype correlation of hereditary erythrocytosis mutations, a single center experience. American Journal of Hematology. 93(8). 1029–1041. 33 indexed citations

18.

Miller, Kevin C., Aref Al‐Kali, Mithun Vinod Shah, et al.. (2018). Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia & lymphoma. 60(4). 990–999. 7 indexed citations

19.

Reichard, Kaaren K., Eric Burks, Carla S. Wilson, et al.. (2005). CD4(+) CD56(+) Lineage-Negative Malignancies Are Rare Tumors of Plasmacytoid Dendritic Cells. The American Journal of Surgical Pathology. 29(10). 1274–1283. 58 indexed citations

20.

Shum, David T., Lyn Guenther, & David S. Viswanatha. (1994). Usefulness of the Dissecting Microscope in the Surgical Management of Skin Cancers. The Journal of Dermatologic Surgery and Oncology. 20(4). 266–271. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact